4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.
Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, today announces that renowned dermato-oncology expert and principal investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will present data from the pivotal RESMAN study of resminostat (Kinselby) at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasadena, California, USA, April 11-13, 2024.
